Alternatively, the B1R antagonist might have reduced T. cruzi infectivity by limiting plasma leakage and the proteolytic formation of infection-inducing peptides, such as BK and DABK [54], at the downstream end of the inflammatory cascade. Here, BDKRB1 is linked to infection.